CompaniesImmunocore
Immunocore logo

Immunocore

active
Abingdon, UK
Founded 2008
Website
About

T Cell Receptor Fragment Therapies

Areas of Focus

Categories

Biologics & Biopharmaceutical
Team (28)
Andrew Hooker, PhD
SVP, Chemistry, Manufacturing & Controls (CMC) and Supply Chain
Immunocore
team_member
Annelise Vuidepot, PhD
SVP, Chief Technology Officer, Research and UK Site Lead
Immunocore
executive
Bahija Jallal, PhD
Chief Executive Officer
Immunocore
executive
Clayton Robertson
Head of Investor Relations
Immunocore
team_member
David Berman, MD, PhD
EVP, Research and Development
Immunocore
team_member
Debra Nielsen
VP, Chief of Staff
Immunocore
executive
View all 28 team members →
Clinical Trials (18)
View all

Total Trials

18

As Lead Sponsor

14

As Collaborator

4

Total Enrollment

4,541

By Phase

PHASE2: 5PHASE3: 3PHASE1: 3PHASE1/PHASE2: 6

By Status

RECRUITING: 8WITHDRAWN: 3ACTIVE_NOT_RECRUITING: 2TERMINATED: 2COMPLETED: 2AVAILABLE: 1
Clinical Trials Pipeline17 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
NCT01211262
NCT02535078
NCT02570308
NCT03070392
NCT03973333
NCT04262466
NCT05867056
NCT05315258
NCT05549297
NCT06840119
NCT07156136
NCT06246149
NCT06627244
NCT06070012
Hover over trial bars to see details

Recent Trials

NCT06070012Collaborator
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
PHASE2Recruiting
44 participants
Started: Mar 10, 2025 · Completed: Mar 31, 2030
NCT06627244Collaborator
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
PHASE2Recruiting
30 participants
Started: Feb 14, 2025 · Completed: Feb 17, 2031
NCT06246149Collaborator
Adjuvant Tebentafusp in High Risk Ocular Melanoma
PHASE3Recruiting
290 participants
Started: Nov 11, 2024 · Completed: Nov 30, 2032
NCT07156136Lead Sponsor
Study of IMC-P115C in Advanced PRAME-Positive Cancers
PHASE1Recruiting
140 participants
Started: Nov 7, 2024 · Completed: Aug 30, 2029
NCT06112314Lead Sponsor
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
PHASE3Recruiting
680 participants
Started: Jun 5, 2024 · Completed: Oct 16, 2027
View all 18 trials →
Funding History (16)
8-K
Aug 7, 2025
Filing
8-K
May 15, 2025
Filing
8-K
May 7, 2025
Filing
DEF 14A
Apr 4, 2025
Filing
8-K
Mar 17, 2025
Filing
8-K
Mar 10, 2025
Filing
8-K
Feb 26, 2025
Filing
8-K
Jan 10, 2025
Filing
8-K
Jan 2, 2025
Filing
8-K
Nov 8, 2024
Filing
Locations (1)
Headquarters
Abingdon, UK
Map

Loading map...